Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2018
At a glance
- Drugs AL 101 (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma; T cell lymphoma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 29 May 2018 Status changed from active, no longer recruiting to completed.
- 30 Jan 2018 Planned End Date changed from 29 Jun 2018 to 1 Jul 2018.
- 30 Jan 2018 Planned primary completion date changed from 29 Jun 2018 to 28 Jun 2018.